Skip to main content

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

The Original Article was published on 16 June 2023

Correction: BMC Ophthalmol 23, 279 (2023)

https://doi.org/10.1186/s12886–023-03012-1

After publication of the original article [1], the author group noticed a calculation error that has affected Tables 3 and 5 as well as the second paragraph of the Results section in page 4.

The original article has been updated and the correct values are also given below in bold.

Table 3 Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 25 mg/dL and propensity score-matched patients on placebo
Table 5 Baseline lipid parameters in patients on alirocumab with ≥ 2 consecutive LDL-C values < 15 mg/dL and propensity score-matched patients on placebo

The second paragraph in page 4 should read:

A total of 4305 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 25 mg/dL (0.65 mmol/L) and were matched to 4305 patients from the placebo group with similar baseline characteristics (Tables 2 and 3). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 28.3 kg/m2, LDL-C 2.1 mmol/L, lipoprotein (a) 28.6 mg/dL, and apolipoprotein A1 131.6 mg/dL. A total of 782 patients in the alirocumab group had ≥ 2 consecutive LDL-C values < 15 mg/dL (0.39 mmol/L) and were matched to 2346 patients from the placebo group with similar baseline characteristics (Tables 4 and 5). Baseline characteristics of these patients included mean age 59 years, male sex (81%), diabetes (33%); and mean body mass index 27.3 kg/m2, LDL-C 2.0 mmol/L, lipoprotein (a) 18.8 mg/dL, and apolipoprotein A1 129.9 mg/dL.

Reference

  1. Suc G, Schwartz GG, Goodman SG, et al. Effect of alirocumab on cataracts in patients with acute coronary syndromes. BMC Ophthalmol. 2023;23:279. https://doi.org/10.1186/s12886-023-03012-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Ph.Gabriel Steg.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suc, G., Schwartz, G.G., Goodman, S.G. et al. Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes. BMC Ophthalmol 23, 301 (2023). https://doi.org/10.1186/s12886-023-03065-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12886-023-03065-2